These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
123 related items for PubMed ID: 446076
1. Urinary hydroxyproline in healthy patients and in prostate patients with and without bone metastases. Heller W, Harzmann R, Bichler KH, Schmidt K. Curr Probl Clin Biochem; 1979; (9):249-56. PubMed ID: 446076 [Abstract] [Full Text] [Related]
2. Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer. Rinsho K, Aoyagi K. Tohoku J Exp Med; 1982 Aug; 137(4):461-2. PubMed ID: 7123546 [Abstract] [Full Text] [Related]
3. Urine hydroxyproline excretion--a marker of bone metastases in prostatic carcinoma. Bishop MC, Fellows GJ. Br J Urol; 1977 Aug; 49(7):711-6. PubMed ID: 597712 [Abstract] [Full Text] [Related]
4. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)]. Kurokawa K, Imai K, Yamanaka H, Tomaru Y, Kitaura K. Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558 [Abstract] [Full Text] [Related]
5. [Urinary and serum hydroxyproline in the diagnosis of bone metastases of prostatic cancer]. Gasser AB, Jeannet C, Depierre D, Courvoisier B. Schweiz Med Wochenschr; 1981 Feb 21; 111(8):246-51. PubMed ID: 7233140 [Abstract] [Full Text] [Related]
6. Effect of calcitonin and hexestrol on urinary excretion of hydroxyproline in a patient with prostatic cancer and bone metastases. Matsushita Y, Hasegawa K, Sugimura R, Otomo S, Morii H. Endocrinol Jpn; 1974 Apr 21; 21(2):109-13. PubMed ID: 4408206 [No Abstract] [Full Text] [Related]
7. Urinary hydroxyproline excretion in patients with cancer. Guzzo CE, Pachas WN, Pinals RS, Krant MJ. Cancer; 1969 Aug 21; 24(2):382-7. PubMed ID: 5796782 [No Abstract] [Full Text] [Related]
8. [The diagnostic value of radiological, nuclear medicine and biochemical methods for detection of bone metastases in carcinoma of the prostate (author's transl)]. Rost A, Fiedler U, Marshall F, Koppenhagen K. Radiologe; 1977 Jun 21; 17(6):249-55. PubMed ID: 887744 [Abstract] [Full Text] [Related]
9. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. Miyamoto KK, McSherry SA, Robins SP, Besterman JM, Mohler JL. J Urol; 1994 Apr 21; 151(4):909-13. PubMed ID: 7510346 [Abstract] [Full Text] [Related]
10. Use of urinary hydroxyproline excretion as a tumor marker in diagnosis and follow-up of prostatic carcinoma. Unni Mooppan MM, Kim H, Wang JC, Tobin MS, Wax SH. Prostate; 1983 Apr 21; 4(4):397-405. PubMed ID: 6191318 [Abstract] [Full Text] [Related]
11. Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastases, and patients with primary hyperparathyroidism. Stĕpán JJ, Mikulecký M, Bek V, Broulík P, Pacovský V. Neoplasma; 1989 Apr 21; 36(4):495-501. PubMed ID: 2770935 [Abstract] [Full Text] [Related]
12. [Hydroxyproline in the diagnosis of bone metastases in breast cancer]. Gasser AB, Depierre D, Alberto P, Courvoisier B. Schweiz Med Wochenschr; 1977 Jul 16; 107(28):984-6. PubMed ID: 897640 [Abstract] [Full Text] [Related]
14. Relevance of hydroxyproline excretion to bone metastasis in breast cancer. Gielen F, Dequeker J, Drochmans A, Wildiers J, Merlevede M. Br J Cancer; 1976 Sep 16; 34(3):279-85. PubMed ID: 974001 [Abstract] [Full Text] [Related]
17. [Current status of diagnosis and stage classification of prostatic carcinoma]. Harzmann R, Bichler KH. Med Klin; 1977 Oct 07; 72(40):1649-54. PubMed ID: 199828 [No Abstract] [Full Text] [Related]